Nationwide Fund Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Nationwide Fund Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-20,497	Closed	-$636K	–	2431
2017 Q3	$636K	Sell	20,497 -430	-2%	-$12.1K	﹤0.01%	2059
2017 Q2	$572K	Buy	20,927 +10,266	+96%	+$305K	﹤0.01%	2106
2017 Q1	$393K	Sell	10,661 -113	-1%	-$2.85K	﹤0.01%	2279
2016 Q4	$156K	Sell	10,774 -950	-8%	-$16.7K	﹤0.01%	2716
2016 Q3	$270K	Buy	11,724 +2,624	+29%	+$50K	﹤0.01%	2483
2016 Q2	$151K	Buy	9,100 +4,588	+102%	+$92.6K	﹤0.01%	2746
2016 Q1	$72K	Sell	4,512 -9,510	-68%	-$169K	﹤0.01%	2914
2015 Q4	$453K	Buy	14,022 +12,323	+725%	+$534K	﹤0.01%	2160
2015 Q3	$72K	Buy	+1,699	New	+$80.2K	﹤0.01%	2974

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nationwide Fund Advisors's GBT Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2017, closing a stake of 20,497 shares — an estimated $636K sold.

Nationwide Fund Advisors first reported a position in GBT in Q3 2015 and held it in 9 quarters. The position peaked at $636K in Q3 2017. 157 funds tracked by Wall St. Rank hold GBT as of Q4 2017.

Nationwide Fund Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 20,497 Global Blood Therapeutics, Inc. shares in Q4 2017, an estimated $636K.
Nationwide Fund Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
Nationwide Fund Advisors's Global Blood Therapeutics, Inc. position peaked at $636K in Q3 2017.
157 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.